Vascular Disease, Hypertension, and Prevention

Journal of the American College of Cardiology

Volumn 47, Issue 11 SUPPL., 2006, Pages

  McLean, Rhondalyn C ^a   Mohler, Emile R ^b   Blumenthal, Roger S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; AMLODIPINE; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METOPROLOL; PIOGLITAZONE; PRAVASTATIN; ROSUVASTATIN;

ACUTE CORONARY SYNDROME; ADDITION REACTION; ATHEROSCLEROSIS; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERTENSION; INHIBITION KINETICS; ISCHEMIC HEART DISEASE; METABOLIC SYNDROME X; OBESITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROPHYLAXIS; REPERFUSION; REVIEW; RISK FACTOR; RISK REDUCTION; ST SEGMENT ELEVATION; THROMBOCYTE; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; VASCULAR DISEASE;

CARDIOVASCULAR DISEASES; HUMANS; HYPERTENSION; VASCULAR DISEASES;

EID: 33646946765     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2006.04.015     Document Type: Review

References (21)

1. Price M.J., and Wong G.B. Variability in the recovery of platelet function after discontinuation of clopidogrel therapy. (abstr). J Am Coll Cardiol 47 Suppl A (2006) 379A
2. Schweiger M.J., Giugliano G.R., Lotfi A., Murphy S.A., and Cannon C.P. High dose atorvastatin does not impact the efficacy of clopidogrel-a PROVE IT TIMI-22 analysis. (abstr). J Am Coll Cardiol 47 Suppl A (2006) 380A
3. Sabatine M.S., Cannon C.P., Gibson C.M., et al., CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352 (2005) 1179-1189
4. Chen Z.M., Jiang L.X., Chen Y.P., et al., COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) Collaborative Group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction. randomised placebo-controlled trial. Lancet 366 (2005) 1607-1621
5. Yusuf S., Zhao F., Mehta S.R., et al., Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
6. Steinhubl S.R., Berger P.B., Mann III J.T., et al., CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. a randomized controlled trial. JAMA 288 (2002) 2411-2420
7. Bhatt D.L., Topol E.J., Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and and Avoidance Executive Committee. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention. rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J 148 (2004) 263-268
8. Bhatt D.L., Fox K.A., Hacke W., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354 (2006) 1706-1717
9. Nissen S.E., Tuzcu E.M., Libby P., et al., CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 292 (2004) 2217-2225
10. Baghdasarian S.B., Thompson P.D., Shi H., et al. Effect of amlodipine and enalapril on cardiovascular events in normotensive coronary artery disease patients with concomitant statin use in the CAMELOT trial. (abstr). J Am Coll Cardiol 47 Suppl A (2006) 310A
11. Baghdasarian S.B., Thompson P.D., Shi H., et al. Effect of amlodipine and enalapril on cardiovascular events in patients with insulin resistance and diabetes in the CAMELOT trial. (abstr). J Am Coll Cardiol 47 Suppl A (2006) 309A
12. Menzin J., Boulanger L., Tang S., Thakker K.M., and Nissen S.E. Effects of amlodipine or enalapril versus placebo on rates of cardiovascular hospitalization and costs among coronary artery disease patients with normal blood pressure. findings from the CAMELOT economic substudy. (abstr). J Am Coll Cardiol 47 Suppl A (2006) 361A
13. Sipahi I., Tuzcu E.M., Nicholls S.J., et al. Use of beta-blockers and progression of coronary atherosclerosis. an intravascular ultrasound analysis from the CAMELOT study. (abstr). J Am Coll Cardiol 47 Suppl A (2006) 320A
14. Sipahi I., Tuzcu E.M., Nicholls S.J., et al. Effects of optimal versus high normal blood pressure on progression of coronary atherosclerosis. insight from the CAMELOT study. (abstr). J Am Coll Cardiol 47 Suppl A (2006) 343A
15. Nissen S.E., Nicholls S.J., Sipahi I., et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. the ASTEROID trial. JAMA 295 (2006) 1556-1565
16. Hoang K., Lopez V.A., Barboza M.A., and Wong N.D. Global risk assessment of U.S. persons with the metabolic syndrome. (abstr). J Am Coll Cardiol 47 Suppl A (2006) 310A
17. Kasai T., Miyauchi K., Njaman W., et al. The impact of metabolic syndrome and diabetes on long-term outcomes following percutaneous coronary interventions. (abstr). J Am Coll Cardiol 47 Suppl A (2006) 326A
18. Mohlenkamp S., Schmermund A., Lehmann N., et al. A predisposition for the metabolic syndrome increases subclinical inflamed coronary plaque burden in low Framingham risk score women from a general population. (abstr). J Am Coll Cardiol 47 Suppl A (2006) 312A
19. Murakami T., and Kokado H. Long-term administration of pioglitazone reverses arteriosclerotic processes in type-2 diabetics. (abstr). J Am Coll Cardiol 47 Suppl A (2006) 321A
20. Purushothaman K.-R., Fuster V., Sirol M., et al. Diabetic plaque inflammation and neovascularization are associated with increased reparative collagen content. implication for plaque progression in diabetic atherosclerosis. (abstr). J Am Coll Cardiol 47 Suppl A (2006) 295A
21. Suk Danik J., Rifai N., Buring J.E., and Ridker P.M. Plasma concentration of lipoprotein(a) and the risk of future cardiovascular disease in women. (abstr). J Am Coll Cardiol 47 Suppl A (2006) 314A